Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methanesulfonic Acid Ethyl Ester SCHEMBL5533648 | 0.94 | CA1 (0.53) | USP2TSHRCA1CA2ALDH1A1 | |
| Methanesulfonic Acid Ethyl Ester SCHEMBL2296 | 0.94 | — | — | |
| Methanesulfonic Acid Ethyl Ester SCHEMBL28241242 | 0.90 | CA1 (0.50) | USP2TSHRCA1CA2ALDH1A1 | |
| Methanesulfonic Acid Ethyl Ester SCHEMBL28179907 | 0.90 | — | — | |
| Methanesulfonic Acid Ethyl Ester SCHEMBL5666892 | 0.90 | — | — | |
| Methanesulfonic Acid Ethyl Ester SCHEMBL28114804 | 0.90 | — | — | |
| Methanesulfonic Acid Ethyl Ester SCHEMBL28142893 | 0.90 | — | — | |
| Methanesulfonic Acid Ethyl Ester SCHEMBL31396011 | 0.90 | — | — | |
| Methanesulfonic Acid Ethyl Ester SCHEMBL2461930 | 0.85 | TSHR (0.46) | USP2TSHRCA1CA2ALDH1A1 | |
| Methanesulfonic Acid Ethyl Ester SCHEMBL27450293 | 0.85 | CA1 (0.46) | USP2TSHRCA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152261-A1 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-06-17 | — | — | US | disclosed |
| EP-1939183-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152261-A1 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM3, CHRM2, CHRM1 | USP2 2398/4885TSHR 381/4885CA1 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.